LifeMD Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs

LifeMD’s virtual care services now available to over 21 million Medicare Part B beneficiaries in 26 states, with 49-state access to qualifying services expected by the end of Q2

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states anticipated by the end of the second quarter.

"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step forward in expanding access to essential care for older Americans. This launch follows two years of focused investment in operational readiness and regulatory compliance, positioning LifeMD to serve the growing Medicare population with confidence and at scale,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.

“A significant portion of the Medicare population lacks convenient access to a primary care provider – especially in rural or underserved areas – making it difficult for older adults to receive timely, preventive care. At the same time, approximately 75% of Medicare beneficiaries are overweight, obese, or managing at least one cardiometabolic condition such as type 2 diabetes, hypertension, or high cholesterol. We believe LifeMD’s direct-to-patient virtual care platform and 50-state affiliated provider group are uniquely positioned to expand access and improve outcomes for this critical population segment.”

“Virtual consultations for patients with obesity and other chronic conditions are covered by Medicare Part B when medically necessary, yet Medicare Part D coverage for GLP-1 medications is currently generally limited to patients with cardiovascular conditions and obstructive sleep apnea, in the case of Zepbound, among others,” he added. “Despite this, recent polls have shown overwhelming bipartisan support for Medicare and Medicaid coverage of GLP-1 drugs. We remain optimistic that a near-term solution will emerge to enable broader access to these life-saving medications.”